RxDoctor Payments Data

Mary Elfrey, DO

Cardiovascular Disease · Baltimore, MDNPI 1760645519

Payments from drug & device makers

$3,667in general payments, 2019–2025

Across 195 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$775
  • E.r. Squibb & Sons, L.L.C.$425
  • Amgen$354
  • Boehringer Ingelheim$321
  • Novo Nordisk$303
  • Baxter Healthcare$195
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,667 in reported general payments places this provider in the 60th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$266,392
Medicare patients
974
Services billed
2,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$243,685
JardianceEmpagliflozin74$93,994
EntrestoSacubitril/Valsartan68$82,804
XareltoRivaroxaban40$42,858
Repatha SureclickEvolocumab41$29,820
OzempicSemaglutide13$13,283
Metoprolol Succinate299$5,542
Ezetimibe72$4,925
Rosuvastatin Calcium137$4,362
Losartan Potassium215$2,735
Atorvastatin Calcium218$2,486
Amiodarone Hcl30$1,398
Hydralazine Hcl87$1,270
Amlodipine Besylate159$944
Valsartan27$885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$98$243,685206 claims
Boehringer IngelheimJardiance$321$93,99474 claims
NovartisEntresto$775$82,80468 claims
Johnson & JohnsonXarelto$173$42,85840 claims
Novo NordiskOzempic$303$13,28313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →